Abstract
14 patients with chronic progressive multiple sclerosis, selected in a preliminary uncontrolled trial, were given a short course of intensive cyclophosphamide therapy, which was discontinued when the leukocyte count fell to 3000 cu.mm. 5 patients dropped out because of severe side effects. At 1 year follow-up were neurologically unchanged since admission to the trial; 4 remained stable at 2 years. The lack of clinical improvement, the high frequency of side effects and the proven oncogenicity of cyclophosphamide led us to discontinue the trial.
Sommario
14 pazienti con SM definita e con forma cronica severamente progressiva sono stati trattati con un ciclo a breve termine e ad alto dosaggio di ciclofosfamide (400 mg/die), associata a cortisone (100 mg/die). L'immunosoppressione è stata considerata efficace quando è stata raggiunta una leucopenia di 3.000/mmc e a quel momento il farmaco è stato interrotto. 5 pazienti non hanno terminato il trattamento per la comparsa di gravi effetti collaterali. Dopo 1 anno di follow-up tutti i pazienti erano stazionari rispetto all'ingresso; 4 pazienti hanno terminato il secondo anno di follow-up e in essi la malattia si è mantenuta in fase di stabilizzazione. Nonostante questo, l'assenza di miglioramenti clinici, l'alta frequenza di effetti collaterali, la dimostrata oncogenicità della ciclofosfamide non ci incoraggia a continuare la sperimentazione.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brown J.R., Beebe G.W., Kurtzke J.F., Silberberg D.H.:The design of clinical studies to assess therapeutic efficacy in MS. Neurol. 29, 3–23; 1979.
Drachman D.A., Paterson P.Y., Schmidt R.T., Spehlmann R.F.:Cyclophosphamide in exacerbations of MS. J Neurol. Neurosur. Psychiat. 38, 592–97, 1973.
Gonsette R.E., Delmotte P.:Intensive immunosuppression with cyclophosphamide in MS. J. Neurol. 214, 173–81, 1977.
Hauser S.L.:Intensive immunosuppression in progressive MS, a randomized, three-arm study of high dose intravenous cyclophosphamide, plasmaexchange and ACTH. New Engl. J. Med. 4, 173–180, 1983.
Hauser S.L.:Cyclophosphamide treatment in MS. Immunotherapy of MS. Eur. Neurol., 24, 433–41, 1985.
Hommes O.R.:Immunosuppressive treatment in chronic progressive MS, in: Delmotte P., Hommes O.R., Gonsette R. (editors): Immunosuppressive treatment in MS, European Press, 48–64, 1980.
Kurtzke J.F.:Rating neurological impairment in MS: an expanded disability status scale Neurol., 33, 1444–452, 1983.
McFarlin D.E., McFarland H.F.:Multiple sclerosis. New. Engl. J. Med., 19, 1183–88; 1246–50; 1982.
Noseworthy J.H., Seland T.P., Ebers G.C.:Therapeutic trials in MS. J. Can. Sci. Neurol., 11, 355–62, 1984.
Plotz P.H., Klippel J.H., Decker J.L.:Bladder complications in patients receiving cyclophosphamide for LES or rheumatoid arthritis. Ann. Inter. Med., 91, 221–3, 1979.
Schumacher G.A., Beebe G., Kibler R.F.:Problems of experimental trials of therapy in MS Ann. NY Acad. Sci., 122, 552–568, 1965.
Theys P., Gosseve-Lissoir F., Ketelaer P., Carton H.:Short-term intensive cyclophosphamide treatment in MS. J. Neurol. 225, 119–133, 1981.
Weiner H.L., Hauser S.L.:Immunoregulation in neurological disease, Ann. Neurol. 11, 437–49, 1982.
Weiner H.L., Ellison G.W.:A working protocol to be used as a guideline for trials in MS. Arch. Neurol. 40, 704–10, 1983.
Wekerle H.:Evidence from basic research justifying immunotherapy in MS. Eur. Neurol. 24, 433–41, 1985.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Siracusa, G.F., Amato, M.P., Fratiglioni, L. et al. Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis. Ital J Neuro Sci 8, 589–592 (1987). https://doi.org/10.1007/BF02333666
Issue Date:
DOI: https://doi.org/10.1007/BF02333666